Integration of genomic sequencing drives therapeutic targeting of PDGFRA in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.
Jonathan D PaolinoBoris DimitrovBeth Apsel WingerAngélica Sandoval-PérezAmith Vikram RangarajanNicole Ocasio-MartinezHarrison K TsaiYuting LiAmanda L RobichaudDelan KhalidCharles HattonRiaz GillaniPetri PolonenAnthony DiligGiacomo GottiJulia KavanaghAsmani A AdhavSean GowJonathan M TsaiYen-Der LiBenjamin L EbertEliezer Van AllenJacob R BledsoeAnnette S KimSarah K TasianStacy L CooperTodd M CooperNobuko HijiyaMaria-Luisa SulisNeerav N ShuklaJeffrey A MageeCharles G MullighanMichael J BurkeMarlise R LuskinBrenton G MarMatthew P JacobsonMarian H HarrisKimberly StegmaierAndrew E PlaceYana PikmanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Refractory T-ALL has not been fully characterized. Alterations in PDGFRA or other targetable kinases may inform therapy for patients with refractory T-ALL who otherwise have limited treatment options. Clinical genomic profiling, in real time, is needed for fully informed therapeutic decision making.